Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Inclusion Criteria

• •Diagnosis of hematologic cancer or other disease, including any of the following:
• •* Chronic myelogenous leukemia in first or second chronic phase
• •* Acute lymphoblastic leukemia (ALL), meeting any of the following criteria:
• •* Relapsed ALL enrolled on a Children's Oncology Group (COG) relapse clinical trial OR received ≥ 1 round of reinduction therapy (4-6 weeks) and 1 round of intensive consolidation chemotherapy (3-6 weeks)
• •* ALL in second complete remission (CR)\* after a bone marrow, extramedullary, or combined bone marrow and extramedullary relapse
• •* Very high-risk ALL in first CR, defined as any of the following:
• •* Philadelphia chromosome-positive ALL
• •* Hypodiploidy (\< 44 chromosomes)
• •* Mixed lineage leukemia rearrangement
• •* Induction failure
• •* Acute myeloid leukemia in first or second CR
• •* Induction therapy must be completed
• •* Juvenile myelomonocytic leukemia
• •* Myelodysplastic syndromes
• •No clinically evident CNS or extramedullary disease
• •No blasts seen on cerebrospinal fluid cytospin
• •Post-relapse reinduction therapy must be completed
• •Not planning to receive reduced-intensity conditioning regimen
• •Not planning to receive a graft that has undergone T-cell depletion
• •No Down syndrome
• •Matched sibling donor must be available and must be enrolled on ASCT0631D companion study
• •Karnofsky performance status (PS) 60-100% (patients \> 16 years of age) OR Lansky PS 60-100% (patients ≤ 16 years of age)
• •AST or ALT \< 5 times upper limit of normal for age
• •Bilirubin \< 2.5 mg/dL (unless due to Gilbert's syndrome)
• •Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base on age and/or gender as follows:
• •* 0.4 mg/dL (1 month to \< 6 months of age)
• •* 0.5 mg/dL (6 months to \< 1 year of age)
• •* 0.6 mg/dL (1 to 2 years of age)
• •* 0.8 mg/dL (2 to \< 6 years of age)
• •* 1.0 mg/dL (6 to \< 10 years of age)
• •* 1.2 mg/dL (10 to \< 13 years of age)
• •* 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \< 16 years of age)
• •* 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)
• •Shortening fraction ≥ 27% by echocardiogram OR LVEF ≥ 50% by radionuclide angiogram
• •FEV\_1, FVC, and DLCO ≥ 60% OR meets the following criteria (for patients unable to cooperate for pulmonary function tests):
• •* No evidence of dyspnea at rest
• •* No exercise intolerance
• •* No requirement for supplemental oxygen therapy
• •Not pregnant or nursing
• •No known HIV
• •No known uncontrolled fungal, bacterial, or viral infections
• •* Patients acquiring fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT scan
• •No prior allogeneic or autologous stem cell transplantation